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ABSTRACT
Pseudomonas aeruginosa isolates (n = 183), collec-
ted from bacteraemic patients hospitalised in Sa˜o
Paulo Hospital (Brazil) during 2000–2001, were
screened for susceptibility to antimicrobial agents.
The polymyxins were the most active compounds
(100% susceptibility), followed by amikacin and
cefepime (59.0%), meropenem (57.4%), and imi-
penem and gentamicin (55.2%). Imipenem-resist-
ant isolates were ribotyped and screened for
production of metallo-b-lactamases (MBLs) by
PCR with primers for blaIMP, blaVIM and blaSPM.
MBL production was detected in 36 isolates
(19.7% of the entire collection; 43.9% of the
imipenem-resistant isolates) and the MBLs inclu-
ded SPM-1-like (55.6%), VIM-2-like (30.6%) and
IMP-1-like (8.3%) enzymes.
Keywords Carbapenem resistance, imipenem resist-
ance, metallo-b-lactamases, polymyxin, Pseudomonas
aeruginosa
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Pseudomonas aeruginosa is a leading cause of
hospital-acquired infections that are often difﬁcult
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to treat because of the limited choice of effective
antimicrobial agents. Carbapenems, mainly imi-
penem and meropenem, are potent agents for the
treatment of infections caused by multiresistant
Gram-negative bacilli, especially P. aeruginosa.
Resistance to carbapenems in P. aeruginosa has
mostly been low level (MIC 8–32 mg ⁄L), and
associated with reduced uptake as a result of
OprD porin loss [1]. Resistance by this mechanism
depends on continued expression of the chromo-
somal AmpC b-lactamase. Low-level carbapenem
resistance can also arise via over-expression of
efﬂux pumps. However, production of metallo-
b-lactamases (MBLs) is now being reported
increasingly as a cause of high-level carbapenem
resistance (MIC > 32 mg ⁄L) in P. aeruginosa [1–3].
The MBL types are IMP, VIM and the recently
described SPM [2–4]. The objective of the present
study was to detect and characterise P. aeruginosa
isolates producing MBLs in a teaching hospital
located in Sao Paulo, Brazil.
The present study investigated all P. aeruginosa
isolates (n = 183) from bloodstream infections
(one isolate ⁄patient) during 2000 and 2001 at the
Sa˜o Paulo Hospital complex, which is a 600-bed
tertiary care university hospital. The isolates were
tested initially by disk diffusion [5] against
imipenem, meropenem, aztreonam, cefepime,
ceftazidime, amikacin, gentamicin, ciproﬂoxacin
and polymyxin B. All isolates that were non-
susceptible to imipenem or meropenem were then
retested by broth microdilution (Trek Diagnostics
Systems, East Grinstead, UK) according to
NCCLS protocols [6] against the same group of
antimicrobial agents (except that polymyxin B
was replaced by colistin) plus piperacillin–tazo-
bactam. Quality control strains were P. aeruginosa
ATCC 27853, Escherichia coli ATCC 25922 and
Staphylococcus aureus ATCC 29213. Isolates resist-
ant to both imipenem and meropenem were
screened initially for MBL production by the disk
approximation test, with ceftazidime and imipe-
nem as substrates, and EDTA and 2-mercapto-
propionic acid as b-lactamase inhibitors [7]. The
results were conﬁrmed with Etest MBL strips (AB
Biodisk, Solna, Sweden) [8].
All isolates positive for MBL production were




3¢ and antisense 5¢-TGTGCTTTGACAACGTTCGC-3¢
primers), blaVIM-2 (sense 5¢-ATGTTCAAACTTTT-
GAGTAGTAAG-3¢ and antisense 5¢-CTACTCAAC-




The genetic similarity of the 47 imipenem-
resistant isolates (MIC ‡ 16 mg ⁄L) isolated in
2001 was investigated by automated ribotyping
with the RiboPrinter Microbial Characterization
System (DuPont de Nemours, Wilmington, DE,
USA) [9]. In brief, this automated process includes
lysis of overnight cell cultures, cleavage of DNA
with the restriction enzyme PvuII, size separation
by means of gel electrophoresis, and modiﬁed
Southern blotting. Results were analysed with the
Riboprinter system, and isolates were considered
to have an identical ribotype if the similarity
coefﬁcient was ‡ 0.93.
Overall, 82 (44.8%) of 183 P. aeruginosa isolates
from bloodstream infections in 2000 and 2001
were resistant to imipenem. The highest suscep-
tibility (by disk diffusion) was to polymyxin B
(100%), followed by amikacin and cefepime
(59.0%), meropenem (57.4%), imipenem and gen-
tamicin (55.2%), piperacillin–tazobactam (54.6%),
ciproﬂoxacin (53.5%), ceftazidime (51.4%) and
aztreonam (47.5%). Against imipenem-resistant
isolates (n = 82), the most active compound was
colistin or polymyxin E (MIC90 £ 0.5 mg ⁄L; 100%
susceptible), followed by aztreonam (MIC50,
32 mg ⁄L; 34.1% susceptible), cefepime (MIC50,
16 mg ⁄L; 29.2% susceptible) and amikacin
(MIC50, > 64 mg ⁄L; 29.2% susceptible).
MBL production was detected in 36 isolates,
representing 19.7% of the 183 isolates investi-
gated, or 43.9% of the 82 imipenem-resistant
isolates. Among the MBL-producing isolates, 20
(55.6%) were positive by PCR for blaSPM-1, 11
(30.6%) were positive for blaVIM-2, and three
(8.3%) were positive for blaIMP-1. Two (5.6%)
isolates did not produce PCR ampliﬁcation prod-
ucts with any of the primers used (Table 1). Apart
from the polymyxins (100% susceptibility), aztre-
onam (55.5% susceptibility) was the most active
antimicrobial agent against the MBL-producing
isolates. All isolates producing an SPM-1-like
ampliﬁcation product were susceptible to aztreo-
nam. Susceptibilities to piperacillin–tazobactam
and amikacin were 27.7% and 25.0%, respect-
ively. All other compounds tested were active
against < 15% of the 36 MBL-producing isolates.
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Analysis of genetic similarity by ribotyping
showed great clonal diversity among the
47 imipenem-resistant isolates collected in 2001.
Twenty-ﬁve ribogroups were identiﬁed, and ﬁve
of those were represented by more than one
isolate (Table 1). Seven ribogroups were identi-
ﬁed among blaSPM-1-positive isolates, three ribo-
groups were found among blaVIM-2-positive
isolates, and all three blaIMP-1-positive isolates
had distinct ribogroups.
Although the production of MBL is uncommon
among clinical isolates of P. aeruginosa in other
parts of the world, this mechanism is becoming
increasingly more common in Brazil and other
Latin American countries [10,11]. After the ﬁrst
report of SPM-1 (Sa˜o Paulo metallo-
b-lactamase) in a P. aeruginosa isolate from this
hospital (isolate 1088 in Table 1) [4], this enzyme
has disseminated throughout Brazil [10].
The present study showed that P. aeruginosa
isolates causing bloodstream infections in the Sa˜o
Paulo Hospital complex had high rates of resist-
ance to most antimicrobial agents evaluated, and
only the polymyxins showed consistent in-vitro
activity. However, the role of aztreonam in the
treatment of infections caused by isolates produ-
cing SPM-1-like enzymes should be evaluated
further.
The correlation between carbapenem usage and
resistance to these compounds has been difﬁcult to
establish [12]. Although the use of carbapenems in
the Sa˜o Paulo Hospital complex is restricted to
treatment of infections caused by Gram-negative
bacilli resistant to all other compounds, or for very
special conditions, both imipenem and merope-
nem are now used routinely to treat P. aeruginosa
infections because of the high rates of resistance to
other compounds. The yearly usage of these two
carbapenems combined varied from 1.7 to
3.8 g ⁄ 1000 patient-days in the entire hospital,
and from 16.1 to 20.7 g ⁄ 1000 patient-days in the
intensive care unit, during 1996–2001. In the same
period, several clusters of infections caused by
imipenem-resistant isolates with an identical or
similar molecular ﬁngerprinting pattern were
identiﬁed. Thus, both factors (high usage of
carbapenems and clonal dissemination of resistant
strains) may be contributing to the increasing
frequency of carbapenem-resistant P. aeruginosa in
this hospital.
Production of MBLs represents an important
mechanism of resistance to carbapenems and
other b-lactams among P. aeruginosa isolates in
this hospital. One in ﬁve P. aeruginosa isolates
from bloodstream infections produced an MBL,
and three types of MBL (IMP, VIM and SPM)
were detected. The observed genetic diversity
among isolates producing each type of MBL
indicates that both horizontal and clonal dis-
semination of these genes has occurred in the
hospital. Strict infection control measures should
be implemented to prevent further spread of
these potent MBLs.
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Table 1. Demographics and molecular results of the 36




(day/month/year) Hospital unit Ribogroup PCR
1191 26 ⁄ 3 ⁄ 2001 Internal Medicine 87-3 IMP-1-like
1260 24 ⁄ 4 ⁄ 2001 Internal Medicine 90-5 IMP-1-like
955 16 ⁄ 1 ⁄ 2001 Internal Medicine 92-3 IMP-1-like
1111 20 ⁄ 2 ⁄ 2001 Internal Medicine 87-2 SPM-1-like
1991 18 ⁄ 12 ⁄ 2001 Dialysis 97-7 SPM-1-like
1971 12 ⁄ 12 ⁄ 2001 Pneumology 97-7 SPM-1-like
1088a 25 ⁄ 2 ⁄ 2001 Oncohaematology 2 87-2 SPM-1-like
1104 21 ⁄ 2 ⁄ 2001 Oncohaematology 2 87-2 SPM-1-like
1110 17 ⁄ 2 ⁄ 2001 Oncohaematology 2 87-2 SPM-1-like
1129 8 ⁄ 3 ⁄ 2001 Oncohaematology 2 87-2 SPM-1-like
1212 11 ⁄ 4 ⁄ 2001 Oncohaematology 2 87-2 SPM-1-like
1228 17 ⁄ 4 ⁄ 2001 Oncohaematology 2 87-2 SPM-1-like
1621 8 ⁄ 9 ⁄ 2001 Oncohaematology 2 89-5 SPM-1-like
1638 9 ⁄ 9 ⁄ 2001 Oncohaematology 2 89-6 SPM-1-like
929 3 ⁄ 1 ⁄ 2001 Oncohaematology 2 92-1 SPM-1-like
956 15 ⁄ 1 ⁄ 2001 Oncohaematology 2 92-4 SPM-1-like
971 19 ⁄ 1 ⁄ 2001 Oncohaematology 2 92-5 SPM-1-like
700 5 ⁄ 11 ⁄ 2000 Oncohaematology 2 NT SPM-1-like
813 1 ⁄ 12 ⁄ 2000 Oncohaematology 2 NT SPM-1-like
867 14 ⁄ 12 ⁄ 2000 Oncohaematology 2 NT SPM-1-like
318 10 ⁄ 5 ⁄ 2000 Paediatric ICU NT SPM-1-like
376 8 ⁄ 6 ⁄ 2000 Paediatric ICU NT SPM-1-like
172 21 ⁄ 3 ⁄ 2000 Unknown NT SPM-1-like
1395 24 ⁄ 6 ⁄ 2001 Adult ICU 71-2 VIM-2-like
1280 1 ⁄ 5 ⁄ 2001 Gastroenterology 71-2 VIM-2-like
1231 17 ⁄ 14 ⁄ 2001 Internal Medicine 71-2 VIM-2-like
1364 12 ⁄ 6 ⁄ 2001 Internal Medicine 71-2 VIM-2-like
1483 22 ⁄ 7 ⁄ 2001 Oncohaematology 2 71-2 VIM-2-like
1211 11 ⁄ 4 ⁄ 2001 Adult ICU 87-4 VIM-2-like
1384 20 ⁄ 6 ⁄ 2001 Adult ICU 89-2 VIM-2-like
1916 24 ⁄ 11 ⁄ 2001 Internal Medicine 97-6 VIM-2-like
1665 14 ⁄ 9 ⁄ 2001 Paediatric ICU 89-2 VIM-2-like
290 4 ⁄ 5 ⁄ 2000 Paediatric ICU NT VIM-2-like
483 10 ⁄ 8 ⁄ 2000 Infectious Diseases NT VIM-2-like
1747b 12 ⁄ 10 ⁄ 2001 Oncohaematology 1 71-2 Negative
1918b 26 ⁄ 11 ⁄ 2001 Paediatric ICU 94-7 Negative
ICU, intensive care unit; NT, not typed.
aThe prototype SPM-1 producer [4].
bIsolates with positive phenotypic test results and negative PCR results for all three
primers.
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Cientı´ﬁco e Tecnolo´gico (CNPq, no. 303316 ⁄ 2002-0). The
results were presented in preliminary form at the 43rd
Interscience Conference on Antimicrobial Agents and Chemo-
therapy (ICAAC), Chicago, IL, 14–17 September 2003.
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ABSTRACT
Guidelines recommend high doses of b-lactams
for the therapy of endocarditis. This report des-
cribes a retrospective study of 15 endocarditis
patients (median age 64 years), treated according
to guidelines, whose b-lactam trough plasma
concentrations were measured with high-per-
formance liquid chromatography because of tol-
erance or efﬁcacy concerns. For amoxycillin, the
mean level was 86.8 mg ⁄L (range: 30–212 mg ⁄L);
ﬁve (45%) patients had concentrations > 1000·
MIC. For cloxacillin, the mean level was
47.9 mg ⁄L (range: 16.7–104 mg ⁄L). The conse-
quences of high and unpredicted b-lactam trough
plasma concentrations for a prolonged period
have not yet been thoroughly evaluated.
Keywords b-Lactams, endocarditis, HPLC, pharma-
cokinetics, therapeutic drug monitoring, tolerance
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High doses of b-lactams are used for the treat-
ment of endocarditis [1–3], but treatment guide-
lines do not take into account many factors related
to the host, such as age, sex and liver function,
that may affect b-lactam pharmacokinetics [3,4].
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